Biotage AB Acquires ATDBio
October 20, 2021
Swedish life sciences company Biotage AB has acquired UK-based oligonucleotide specialist ATDBio for approximately £45 million in cash and shares. The deal brings ATDBio’s complex DNA/RNA synthesis capabilities and its founders into the Biotage Group to accelerate capability expansion and scale molecular diagnostics, therapeutics and sequencing support services.
- Buyers
- Biotage AB
- Targets
- ATDBio
- Industry
- Biotechnology
- Location
- Hampshire, United Kingdom
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Integrated DNA Technologies Acquires Swift Biosciences
March 11, 2021
Biotechnology
Integrated DNA Technologies (IDT) has acquired Swift Biosciences, a developer of Next-Generation Sequencing (NGS) library preparation and enrichment kits. The acquisition brings Swift's library prep and enrichment portfolio and Ann Arbor-based team into IDT to expand IDT's NGS product offerings and accelerate growth in academic, translational, and clinical research markets. Financial terms were not disclosed.
-
BioNTech Acquires Biotheus
February 3, 2025
Biotechnology
BioNTech SE has completed the acquisition of clinical-stage biotechnology company Biotheus for $800 million in cash and ADS consideration plus up to $150 million in milestone payments. The deal gives BioNTech full global rights to BNT327 and Biotheus' antibody platform, and adds a local R&D hub and biologics manufacturing facility in China to BioNTech's network to support its oncology strategy.
-
Agilent Technologies Acquires BIOVECTRA for $925M
July 22, 2024
Pharmaceuticals
Agilent Technologies has acquired BIOVECTRA, a Canada-based contract development and manufacturing organization (CDMO), for $925 million. The acquisition — a purchase from H.I.G. Capital — expands Agilent's CDMO capabilities across biologics, HPAPIs, pDNA/mRNA and LNP formulation, and integrates BIOVECTRA into Agilent's Diagnostics and Genomics Group.
-
Takeda Acquires Adaptate Biotherapeutics
January 10, 2022
Biotechnology
Takeda Pharmaceutical Company Limited has exercised its option to acquire Adaptate Biotherapeutics, a UK biotechnology spin-out focused on antibody-based γδ T cell engager therapies for solid tumors. The acquisition gives Takeda Adaptate’s antibody-based γδ T cell engager platform and preclinical pipeline to strengthen Takeda’s immuno-oncology capabilities and accelerate development of Vδ1‑targeting therapies.
-
R-Biopharm AG Acquires AusDiagnostics
June 7, 2022
Biotechnology
German biotechnology company R-Biopharm AG has acquired Australian molecular diagnostics manufacturer AusDiagnostics. The purchase adds AusDiagnostics' multiplex MT-PCR platforms, extraction reagents and laboratory automation capabilities to R-Biopharm's clinical diagnostics portfolio, supporting capability expansion and internationalization into new clinical, veterinary and applied testing markets.
-
Agilent Technologies Acquires Avida Biomed
January 4, 2023
Biotechnology
Agilent Technologies has acquired Avida Biomed, an early-stage developer of high-performance NGS target enrichment workflows for cancer research. The acquisition augments Agilent's SureSelect portfolio and expands its capabilities into high-growth clinical research and diagnostics markets by adding Avida's chemistries and automatable assays compatible with Agilent platforms.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.